Qiu Hu

Qiu Hu


Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 May 2023 in International Journal of Surgery
Verified
Journal Article
Open access
XFXiangli Fan
Xiangli Fan
WJWang JIng
Wang JIng
YCYongshun Chen
Yongshun Chen
QHQiu Hu
Qiu Hu
YTYuanyuan Tian
Yuanyuan Tian
YCYongshun Chen
Yongshun Chen
Background: The efficacy of endoscopic therapy on the long-term survival outcomes of T1b oesophageal cancer (EC) is unclear, this study was designed to clarify the survival outcomes of endoscopic therapy and to construct a model for predicting the prognosis in T1b EC patients. Methods: This study was performed using the Surveillance, Epidemiology, and End Results (SEER) database from 2004 to 2017 of patients with T1bN0M0 EC. Cancer-specific survival (CSS) and overall survival (OS) were compared between endoscopic therapy group, esophagectomy group and chemoradiotherapy group, respectively. Stabilized inverse probability treatment weighting was used as the main analysis method. The propensity score matching method and an independent dataset from our hospital were used as sensitivity analysis. The least absolute shrinkage and selection operator regression (Lasso) was employed to sift variables. A prognostic model was then established and was verified in two external validation cohorts. Results: The unadjusted 5-year CSS was 69.5% (95% CI, 61.5–77.5) for endoscopic therapy, 75.0% (95% CI, 71.5–78.5) for esophagectomy and 42.4% (95% CI, 31.0–53.8) for chemoradiotherapy. After stabilized inverse probability treatment weighting adjustment, CSS and OS were similar in endoscopic therapy and esophagectomy groups (P=0.32, P=0.83), while the CSS and OS of chemoradiotherapy patients were inferior to endoscopic therapy patients (P<0.01, P<0.01). Age, histology, grade, tumour size, and treatment were selected to build the prediction model. The area under the curve of receiver operating characteristics of 1, 3, and 5 years in the validation cohort 1 were 0.631, 0.618, 0.638, and 0.733, 0.683, 0.768 in the validation cohort 2. The calibration plots also demonstrated the consistency of predicted and actual values in the two external validation cohorts. Conclusion: Endoscopic therapy achieved comparable long-term survival outcomes to esophagectomy for T1b EC patients. The prediction model developed performed well in calculating the OS of patients with T1b EC.

26 June 2024 in International Journal of Surgery
Verified
Journal Article
Open access
LXLingling Xia
Lingling Xia
WSWei Shi
Wei Shi
YCYuxin Cai
Yuxin Cai
ZLzhengkai Liao
zhengkai Liao
ZHZhen Huang
Zhen Huang
YCYongshun Chen
Yongshun Chen
Background: For stage T1b-2N0-1 esophageal cancer, the impact of neoadjuvant therapy plus surgery (NS), surgery alone (SA), and surgery plus adjuvant therapy (ST) on cancer-specific survival (CSS) and overall survival (OS) is uncertain. Methods: Stage T1b-2N0-1 esophageal cancer patients from the SEER database and two Chinese cancer centers were included in this study. The Kaplan–Meier method was used to plot survival curves, which were compared using the log-rank test. Propensity score matching was used to equalize differences between the groups. Cox proportional hazards regression models were used to analyze prognostic factors. A nomogram for OS was developed after screening the variables using the Cox proportional hazards regression model and the least absolute shrinkage and selection operator. The performance of the nomogram was assessed by the Harrell concordance index (C-index), the area under the curve (AUC) of the receiver operating characteristic curve, calibration plots, and decision curve analysis. Results: After propensity score matching analysis, the 3-year CSS and OS rates in the NS group compared to the SA group were 80.3% versus 62.1% ( P =0.016) and 75.8% versus 55.5% ( P =0.006), the 3-year CSS and OS rates in the NS group compared to the ST group were 71.3% versus 68.3% ( P =0.560) and 69.8% versus 62.9% ( P =0.330), the 3-year CSS and OS rates in the SA group compared to the ST group were 54.6% versus 66.7% ( P =0.220) and 50.2% versus 57.9% ( P =0.290), respectively. The predictive nomogram for OS in T1b-2N0-1 patients ultimately incorporated five clinicopathological variables: T stage, N stage, age, examined lymph nodes, and therapy modality. The nomogram C-index for predicting OS was 0.648, 0.663, and 0.666 in the training group, external validation group-1, and external validation group-2, respectively. The 1-year, 3-year, and 5-year predicted AUC values of the OS prediction model were 0.659, 0.639, and 0.612 for the training group, and 0.786, 0.758, and 0.692 for validation group-1, and 0.805, 0.760, and 0.693 for validation group-2, respectively. Conclusion: For patients with stage T1b-2N0-1 esophageal cancer, neoadjuvant therapy significantly improves prognosis compared to surgery alone, those presenting with positive lymph nodes after upfront surgery can achieve survival benefits from adjuvant therapy.